Results 191 to 200 of about 262,681 (286)

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

ESC Heart Failure, EarlyView.
Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin.
Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D. Avila, Geurys R. Rojas‐Marte   +7 more
wiley   +1 more source

Relaxin Inhibits Angiotensin II-Induced Cardiac Fibrosis by Activating NO/cGMP Signaling Pathway. [PDF]

Anatol J Cardiol
Liu J, Pan D, Luo Y, Wu W, Jiang T.
europepmc   +1 more source

Real‐world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Large‐scale, real‐world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all‐cause and cause ...
Ankeet S. Bhatt, Muthiah Vaduganathan, Barada P. Jena, Sylwia Suminska, Carlos Eid, Heike Schwende, Michele Senni   +6 more
wiley   +1 more source

Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons. [PDF]

NPJ Parkinsons Dis
Rivas-Santisteban R, Muñoz A, Lillo J, Raïch I, Rodríguez-Pérez AI, Navarro G, Labandeira-García JL, Franco R.   +7 more
europepmc   +1 more source

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF

ESC Heart Failure, EarlyView.
Abstract Aims Sodium–glucose co‐transporter‐2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of
Andrew P. Ambrosy, Andrew J. Sauer, Shachi Patel, Sheryl L. Windsor, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Sanjiv J. Shah, Kavita Sharma, Guillermo Umpierrez, Mikhail N. Kosiborod   +12 more
wiley   +1 more source

Purinergic Receptor Activation Protects Glomerular Microvasculature from Increased Mechanical Stress in Angiotensin II-Induced Hypertension: A Modeling Study. [PDF]

Int J Mol Sci
Richfield O, Cortez R, Kulthinee S, Franco M, Navar LG.   +4 more
europepmc   +1 more source

Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Purpose Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)‐induced cardiomyopathy (DIC).
Wen Chen, Ying Wu, Wei Li, Meiyan Song, Kaizu Xu, Meifang Wu, Liming Lin   +6 more
wiley   +1 more source

Up‐titration of medication in patients with new‐onset heart failure with and without atrial fibrillation

ESC Heart Failure, EarlyView.
Abstract Aims Differences in guideline‐directed medical therapy (GDMT) and clinical outcomes have been observed between heart failure (HF) patients with atrial fibrillation (AF) versus those in sinus rhythm. This study evaluated the effects of up‐titration of HF therapies, consisting of beta‐blockers, angiotensin‐converting‐enzyme inhibitors (ACEis ...
Arietje J.L. Zandijk, Bernadet T. Santema, Friso D.J. Inkelaar, Martje H.L. van der Wal, Janke Warink‐Riemersma, Michiel Rienstra, Adriaan A. Voors   +6 more
wiley   +1 more source

Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study. [PDF]

BMC Cardiovasc Disord
Oguntola BO, Oguntola SO, Ojo OE, Ukpabio PA, Omoaghe AO, Olaniyi KS.   +5 more
europepmc   +1 more source

Real‐world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry

ESC Heart Failure, EarlyView.
Abstract Aims Cardiac resynchronization therapy (CRT) is guideline recommended for the treatment of symptomatic heart failure (HF) with reduced left ventricular ejection fraction and prolonged QRS. However, patients with common comorbidities, such as persistent/permanent atrial fibrillation (AF), are often under‐represented in clinical trials.
Ignacio García‐Bolao, Roy S. Gardner, Daniel Gras, Antonio D'Onofrio, George Mark, Devi Nair, Nicolas Lellouche, Miroslav Novak, Ronald Lo, Engwooi Chew, David Wright, Andrew Kaplan, Matteo Bertini, Sara Veraghtert, Michelle M. Harbin, Elizabeth Matznick, Patrick Yong, Kenneth M. Stein   +17 more
wiley   +1 more source